12790 El Camino Real
Suite 200
San Diego, CA 92130
United States
760 593 4832
https://ventyxbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 79
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Sheila K. Gujrathi M.D. | Executive Chairperson | 125k | N/A | 1970 |
Dr. Raju S. Mohan Ph.D. | Founder, CEO, President & Director | 905.29k | N/A | 1958 |
Dr. John M. Nuss Ph.D. | Chief Scientific Officer | 630.63k | N/A | 1959 |
Dr. Martin Douglas Auster M.D. | Chief Financial Officer | N/A | N/A | 1975 |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Ventyx Biosciences, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.